Of mice and men: why progress in the pharmacological management of obesity is slower than anticipated and what could be done about it?

Obesity is one of the major pandemics of the 21st century. In 2013 –2014, the prevalence of obesity in the US was>35% among men and 40% among women [1]. The World Health Organization (WHO) reported that 39% of men and 39% of women were overweight, and 11% of men and 15% of women were obese in 2016. Thus, approximately 2 billion adults worldwide were overweight and, among them, more than half a billion were obese [2]. Obesity is a chronic disease adversely affecting the quality of life and is associated with many comorbidities, like hypertension, dyslipidemia, type 2 diabetes (T2DM), cardiovascular disease (CVD), nonalcoholic fatty liver disease (NAFLD), chronic kidney disease, particular types of cancer, arthritis and respiratory diseases [3 –6].
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research